More reads

• The obscure advisory committees at the heart of the U.S. drug pricing debate. (Reuters)
• A new Sun Pharma policy on insider trading raises questions of double standards. (STAT Plus)
• How big tech is struggling with the ethics of AI. (Financial Times)
• After amyloid failures, it’s time to take a new tack for treating Alzheimer’s. (STAT)